Neuralink

Neuralink moved from first-in-human implants to a stated 2026 goal of high-volume BCI-device production and near-automated implant surgery.

Who they are

Neuralink is Elon Musk’s brain-computer-interface developer, appearing in coverage as a clinical implant company working to let people with severe paralysis control digital devices and, more recently, as a prospective manufacturer of BCI hardware at scale. Its reporting is closely tied to Musk’s announcements, FDA-regulated human studies, and demonstrations by implant recipients.

The recent arc

Coverage’s central shift has been from permission and proof of concept to patient use. Neuralink said it had received FDA approval for its first-in-human study in May 2023; Musk then said its first device was implanted in a person in January 2024. In March 2024, Wired showed the first patient, a man paralyzed from the shoulders down, playing online chess via the implant, while Reuters and Bloomberg reported second-patient updates in August, including use for 3D design and gaming.

The coverage peak came in 2025Q3, when the story broadened beyond clinical progress into the emerging BCI market. Reuters reported a 1789 Capital investment involving Neuralink, CNBC reported that Neuralink had been approached over Prompt AI, and Sam Altman confirmed plans to fund a rival BCI startup. The most direct subsequent operating claim came in Reuters’ January 2026 report that Musk expects high-volume device production and an almost automated implant procedure during 2026.

The tension

The recurring tension is whether Neuralink can turn a highly invasive, surgically implanted interface into a scalable medical product before rivals define the market differently. OpenAI-backed Merge Labs has been positioned as a competitor, and its hiring of Mikhail Shapiro was reported as suggesting a potentially much less invasive approach. That contrast puts Neuralink’s surgical automation and manufacturing ambitions at the center of its competitive case, while Musk’s prominence makes company milestones inseparable from his broader public profile.

Why it matters

If Neuralink can pair clinical implant performance with repeatable surgery and device production, the BCI category could move from a small number of trial participants toward a more operational medical-technology business. But the coverage also indicates that the route is unsettled: clinical evidence, regulatory execution, and competition from less-invasive approaches will determine whether Neuralink’s implant-led model becomes a durable advantage or one option among several.

Related: Elon Musk · Sam Altman · Elon Musk says that Neuralink implanted its first device in a human on · Neuralink shows its first brain implant patient, a 29-year-old man par · Neuralink says the company received US FDA approval to launch its firs